EZALLOR SPRINKLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EZALLOR SPRINKLE (EZALLOR SPRINKLE).
EZALLOR SPRINKLE (rosuvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing LDL clearance from plasma and reducing VLDL synthesis.
| Metabolism | Minimally metabolized (approximately 10%) via CYP2C9, with no significant metabolism via CYP3A4. Most of the drug is excreted unchanged in feces (90%) and urine (10%). |
| Excretion | Renal excretion accounts for approximately 88% of the administered dose (56% as unchanged rosuvastatin and 32% as metabolites); fecal excretion accounts for approximately 12%. |
| Half-life | Terminal elimination half-life is approximately 19 hours (range 13-20 hours) in healthy volunteers; half-life is prolonged in patients with hepatic impairment and severe renal impairment, necessitating dose adjustments. |
| Protein binding | Approximately 88% bound to plasma proteins, mainly to albumin; binding is reversible and independent of drug concentration. |
| Volume of Distribution | Volume of distribution is approximately 134 L (1.9 L/kg in a 70 kg adult), indicating extensive tissue distribution; distribution is not limited to plasma volume. |
| Bioavailability | Oral bioavailability is approximately 20% (range 10-20%) under fasting conditions; food does not affect the extent of absorption, but may delay Tmax by 1 hour. |
| Onset of Action | Onset of LDL-C reduction is observed within 1 week of oral administration; maximal effect is seen by 2-4 weeks. |
| Duration of Action | Duration of lipid-lowering effect persists for the dosing interval (24 hours) with once-daily dosing; sustained LDL-C reduction is maintained with continued therapy. |
| Molecular Weight | 409.4 |
40 mg orally once daily at bedtime; initial dose may be 20 mg. Dose range: 20-80 mg orally once daily.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <30 mL/min/1.73 m²) or in ESKD on hemodialysis, limit dose to 20 mg orally once daily. |
| Liver impairment | Contraindicated in active liver disease or persistent transaminase elevations >3x ULN. For Child-Pugh Class B, reduce dose by 50% (maximum 40 mg/day). Child-Pugh Class C: contraindicated. |
| Pediatric use | Approved for ages ≥8 years. Starting dose: 5 mg orally once daily; titrate based on LDL-C goal. Maximum dose: 20 mg/day for ages 8-13 and 40 mg/day for ages 14-17. Weight-based: not established; use above age-based guidelines. |
| Geriatric use | Initiate at 20 mg orally once daily; increase only if tolerated and indicated. Monitor for myopathy and renal function. |
| 1st trimester | Not recommended. EZALLOR SPRINKLE (ezetimibe) is contraindicated in pregnancy. Limited human data; animal studies show no teratogenicity but fetal exposure occurs. |
| 2nd trimester | Not recommended. Avoid use during second trimester due to unknown fetal risks. |
| 3rd trimester | Not recommended. Use only if clearly needed; minimal published experience. |
Clinical note
Comprehensive clinical and safety monograph for EZALLOR SPRINKLE (EZALLOR SPRINKLE).
| Placental transfer | Evidence suggests ezetimibe crosses the placenta in animals; human data limited. Molecular weight ≤ 1000 Da implies probable transfer. |
| Breastfeeding | Ezetimibe is excreted in rat milk; human data unavailable. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to ezetimibe or any excipientConcurrent use with a statin in patients with active liver disease or unexplained persistent elevated serum transaminases
| Precautions | Skeletal muscle effects: myopathy/rhabdomyolysis risk increased with higher doses, advanced age, renal impairment, hypothyroidism, and concomitant use of cyclosporine, gemfibrozil, or certain protease inhibitors, Hepatic effects: elevated serum transaminases; monitor liver enzymes before and during therapy, Renal impairment: dose adjustment required for moderate to severe renal disease (CrCl <30 mL/min), Proteinuria: transient dipstick-positive proteinuria reported; clinical significance unclear, Endocrine effects: increased HbA1c and fasting glucose; risk of new-onset diabetes |
| Food/Dietary | No specific food interactions require avoidance. However, consistent timing with meals (with or without food) is recommended to minimize absorption variability. High-fat meals may alter drug absorption; it is generally taken without regard to meals. Grapefruit juice does not interact significantly with ezetimibe. |
Loading safety data…
| Lactation Rating |
| L4 |
| Teratogenic Risk | Pregnancy Category X. Contraindicated in pregnant women due to risk of fetal harm. First trimester: Exposure associated with severe congenital malformations including anencephaly, craniofacial defects, cardiovascular anomalies, and limb defects. Second and third trimesters: Increased risk of fetal growth restriction and fetotoxicity. Effective contraception required before initiation and during therapy. |
| Fetal Monitoring | Monitor maternal complete blood count, liver function tests, and renal function at baseline and periodically. Assess for signs of fetal distress via ultrasound if inadvertent exposure. Counsel on avoidance of pregnancy during therapy. |
| Fertility Effects | May impair female fertility based on animal studies showing decreased implantation and ovarian changes. Male fertility reduced due to testicular degeneration and decreased sperm motility in animal models. Clinical relevance unknown. |
| Clinical Pearls | EZALLOR SPRINKLE (ezetimibe) is a Niemann-Pick C1-Like 1 (NPC1L1) inhibitor that reduces intestinal cholesterol absorption. It is often used as adjunctive therapy to statins or alone in patients intolerant to statins. The sprinkles formulation allows for administration to patients with swallowing difficulties or feeding tubes. Administer with or without food; however, avoid high-fat meals as they may increase variability in absorption. Monitor liver function tests (LFTs) at baseline and periodically, as rare elevations in transaminases have been reported. Concomitant use with fibrates (especially gemfibrozil) increases risk of cholelithiasis; avoid combination. No dose adjustment needed in renal impairment. |
| Patient Advice | Sprinkle the capsule contents onto soft food (e.g., applesauce) and consume within 2 hours; do not chew or crush the granules. · Take exactly as prescribed; do not change dose or stop without consulting your doctor. · Maintain a low-fat diet as directed by your healthcare provider to maximize cholesterol-lowering effects. · Report persistent muscle pain, tenderness, or weakness to your doctor, especially if accompanied by fever or dark urine. · Inform your doctor of all medications, including over-the-counter drugs and supplements, particularly fibrates, bile acid sequestrants, and warfarin. |